Glenn Nedwin, Ph.D., MBA, Co-Founder and President of Novozymes, Inc., to Join Dyadic International as Chief Scientific Officer and President of its Biosciences Business

Nedwin, Ph.D., MBA, Co-Founder and President of Novozymes, Inc., to Join Dyadic

International as Chief Scientific Officer and President of its Biosciences

Fla. - March 21, 2006 - (via Business Wire) - Dyadic

International, Inc. (AMEX: DIL),

biotechnology company, announced today that Glenn E. Nedwin, Ph.D., MBA,

co-founder and President since 1991 of Novozymes, Inc., has been appointed

the positions of Chief Scientific Officer, Executive Vice President and

President of Dyadic's Biosciences Business effective tomrrow, March 22,

2006. Dr. Nedwin also will join Dyadic's Board of Directors.

Novozymes, Inc., a Davis, California-based research & development subsidiary

A/S (Copenhagen Stock Exchange: NZYMb.CO),

Denmark, a global leader in enzymes and microorganisms with over $1 billion

worldwide revenues, Dr. Nedwin was responsible for all scientific, financial

administrative activities, and was a member of Novozymes A/S global R&D

management team and its biosolutions strategy group, and was involved in

technology/product licensing. From 1989 to 1991, Dr. Nedwin served as Vice

President of Corporate Development, Xoma

Corporation (NASDAQ: XOMA),

biotechnology company based in Berkeley, California. Earlier, he was Vice

President, Business Development and co-founder of Ideon Corporation, Redwood

City, California, and Senior Research Scientist and co-founder of Molecular

Therapeutic, Inc. (now Bayer Pharmaceuticals Corporation), West Haven,

Nedwin is a biotechnology pioneer and visionary with more than 24 years of

leadership experience and an unparalleled record of accomplishments in both

scientific and business aspects of our industry," said Mark Emalfarb, President

and CEO of Dyadic. "We are thrilled that he has agreed to join Dyadic, and

forward to his contributions to the development and commercialization of our

proprietary bio-based products. Glenn's success in identifying new product

opportunities and developing and utilizing microbial host production organisms

for the large scale production of enzymes and other bio-based molecules will

invaluable resources for Dyadic as we strive to achieve our growth objectives

and build value for our shareholders."

Dyadic's Chief Scientific Officer, Dr. Nedwin will direct scientific and

development activities and oversee the planned expansion of the company's

R&D efforts. In his capacity as President of the Biosciences Business, Dr.

Nedwin will also be responsible for strategic business development, partnering,

alliances and collaborative research relationships.

Nedwin commented, "I am excited by the opportunity to work with Dyadic's

seasoned management team, its world-renowned Scientific Advisory Board and

of Directors to maximize the potential of the company's rich technology platform

and established large-scale manufacturing capabilities. Dyadic has quickly

established itself as an innovative manufacturer of industrial enzymes with

proprietary C1 fungal strain for highly efficient protein production, a critical

factor for commercialization of industrial products. With the C1 genome sequence

information now in hand, Dyadic's technology is well suited to identify and

produce new enzymes, polymers and chemicals from carbohydrate sources. C1 can

potentially be used to produce enzymes

involved in the production of cellulosic ethanol and other chemicals

from renewable feedstocks. Dyadic's C1 host is also well-suited for low-cost

production of monoclonal antibodies and other therapeutic proteins. I look

forward to the challenge of expanding Dyadic's position in its existing

industrial markets as well as establishing new, higher value opportunities

biofuels and pharmaceuticals."

Nedwin, 50, received his Bachelor of Science degree in Biochemistry from the

State University of New York at Buffalo and his Ph.D. in Biochemistry from

University of California, Riverside. Dr. Nedwin did his postdoctoral fellowship

in molecular biology at Genentech, Inc. Dr. Nedwin also holds an M.S. in the

Management of Technology from the Massachusetts Institute of Technology and

currently a Co-Editor of the Industrial

International, Inc., is engaged in the development, manufacture and sale of

biological products (proteins, enzymes, peptides and other bio-molecules),

well as the licensing of its enabling proprietary technology to business

collaborators for the discovery, development and manufacture of biological

products from genes. Dyadic markets its products and services for applications

in the textile, chemical, agricultural, pulp & paper, pharmaceutical,

biotechnology and other industries, using its proprietary C1 Host Technology

C1 Expression and Screening Systems for the discovery, development and

production of biological products.

Statement for Forward-Looking Statements

statements contained in this press release are "forward-looking statements."

These forward-looking statements involve risks and uncertainties that could

cause our actual results, performance or achievements to be materially different

from any future results, performance or achievements expressed or implied by

such forward-looking statements. For a discussion of these risks and

uncertainties, please see our filings from time to time with the Securities

Exchange Commission, which are available free of charge on the SEC's web site

including our Annual Report on Form 10-KSB for the year ended December 31,

and our Quarterly Report on Form 10-QSB for the quarter ended September 30,

2005. Except as required by law, we expressly disclaim any intent or obligation

to update any forward-looking statements.

(Sasha) Bondar, 561-743-8333